Clinical trials: Hepato Cellular Carcinoma (HCC), active
Hepato Cellular Carcinoma (HCC), Sedation and Analgesia
The Impact of Anaesthesia and Sedation on Inflammation and NETosis in Hepatocellular Carcinoma Ablation
According to recent literature, liver disease causes approximately 2 million deaths annually; 1 million are attributed to the complications of cirrhosis, while the remaining deaths are caused by hepatocellular carcinoma (HCC).
- Conditions
- Hepato Cellular Carcinoma (HCC), Sedation and Analgesia, Ablation Techniques
- Trial name
- NCT07657897
- Testing
- Sedation using combination of Propofol and Fentanyl., Sedation using combination of Propofol and Fentanyl and lidocaine
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Iuliu Hatieganu University of Medicine and Pharmacy
Hepato Cellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma
Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)
Randomized multicentre trial comparing two care organisations (ambulatory vs conventional inpatient) for patients undergoing transarterial chemoembolization (TACE) or radioembolization (TARE) for primary liver cancer (Hepato…
- Trial name
- CHOC (NCT06990659)
- Testing
- Ambulatory care, Conventional inpatient care
- Where
- 19 sites in France
- Volunteers
- 206 people
- Sponsor
- University Hospital, Angers
Hepato Cellular Carcinoma (HCC)
Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab
The purpose of this study is to evaluate whether fecal microbiota transplantation (FMT), when administered in combination with atezolizumab and bevacizumab, can improve treatment response in participants with hepatocellular…
- Trial name
- NCT07276100
- Testing
- Fecal microbiota transplantation (FMT), Atezolizumab & Bevacizumab
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hepato Cellular Carcinoma (HCC), Hand Foot Skin Syndrome
SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin
SHIELD is a single-center, open-label, single-arm prospective study designed to evaluate whether pre-emptive topical indomethacin can reduce sorafenib-associated hand-foot syndrome (HFS) in patients with advanced hepatocellular…
- Trial name
- NCT07560566
- Testing
- Topical Indomethacin
- Where
- Taiwan
- Volunteers
- 39 people
- Sponsor
- National Taiwan University Hospital
Hepato Cellular Carcinoma (HCC)
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
This is a phase II, multi-arm, Bayesian adaptive platform trial designed to efficiently evaluate novel therapies for advanced hepatocellular carcinoma (HCC) after first-line treatment failure.
- Trial name
- HCC-SIGHT (NCT07328009)
- Testing
- Lenvatinib, Regorafenib (BAY 73-4506), Tislelizumab+TKI
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Fudan University
Hepato Cellular Carcinoma (HCC)
Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
This study will evaluate the efficacy and safety of Becotatug vedotin, MRG003, in previously treated advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT07536789
- Testing
- MRG003
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Hepato Cellular Carcinoma (HCC)
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The recurrence rate after curative resection for early-stage HCC remains extremely high, with 2-year and 5-year recurrence rates…
- Trial name
- ACTION-001 (NCT07487662)
- Testing
- sintilimab, ipilimumab N01, Lenvatinib
- Volunteers
- 105 people
- Sponsor
- Sun Yat-sen University
Hepato Cellular Carcinoma (HCC), Renal Cell Cancer
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with nivolumab, how the body processes and responds to WGI-0301…
- Trial name
- NCT07494435
- Testing
- WGI-0301, Nivolumab (240 mg)
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Zhejiang Haichang Biotech Co., Ltd.
Hepato Cellular Carcinoma (HCC), Immunotherapy
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
Our study aims to evaluate the benefit of the administration of immunotherapy (atezolizumab), in patients with hepatocellular carcinoma (HCC), prior surgical resection of the tumor.
- Trial name
- NCT07461675
- Testing
- Atezolizumab
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Geneva, Switzerland
Hepato Cellular Carcinoma (HCC)
Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma
IMPACT-TACE is an investigator-initiated, prospective, multicenter, randomized, double-blinded, interventional trial to test the hypothesis that the simultaneous application of doxorubicin with the ABCB1 inhibitor nicardipine…
- Trial name
- IMPACT-TACE (NCT07302919)
- Testing
- DEB-DoxNic-TACE, current standard of care
- Where
- 3 sites in Switzerland
- Volunteers
- 152 people
- Sponsor
- University Hospital, Basel, Switzerland
Hepato Cellular Carcinoma (HCC), Chemotherapy Effect
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
This is a multi-center randomized phase III clinical study of first-line Camrelizumab and Apatinib with or without intravenous FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma (HCC).
- Trial name
- NCT07267806
- Testing
- Infusional mFOLFOX7 plus Camrelizumab and apatinib, Camrelizumab and apatinib
- Where
- China
- Volunteers
- 326 people
- Sponsor
- Linhui Peng
Hepato Cellular Carcinoma (HCC)
Hepatocellular Carcinoma Identification Using Delta-HLD
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting…
- Trial name
- HIDE (NCT07148310)
- Where
- Argentina
- Volunteers
- 200 people
- Sponsor
- Epiliquid Holding, Inc
Hepato Cellular Carcinoma (HCC), Hepatobiliary Cancers
Effect and Mechanism of ALPPS Operation on Liver Regeneration
Hepatobiliary malignancies-principally hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA)-are highly aggressive and often diagnosed at advanced stages.
- Conditions
- Hepato Cellular Carcinoma (HCC), Hepatobiliary Cancers, Liver Cancer, Liver Regeneration
- Trial name
- NCT07142213
- Testing
- ALPPS
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Haitao Zhao, MD
Hepato Cellular Carcinoma (HCC)
Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma
The goal of this prospective cohort study is to evaluate the role of transient elastography (Fibroscan) in predicting the response of immunotherapy in advanced Hepatocellular carcinoma (HCC) patients.
- Trial name
- NCT06960863
- Testing
- fibroscan
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Tanta University
Hepato Cellular Carcinoma (HCC), Portal Vein Tumour Thrombosis
PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma
The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma…
- Trial name
- NCT06960954
- Testing
- Prothrombin induced by vitamin K absence II (PIVKA-II)
- Where
- Egypt
- Volunteers
- 116 people
- Sponsor
- Tanta University
Hepato Cellular Carcinoma (HCC), Liver Resection
Retrospective Clinical Validation of HepatoPredict
HepatoPredict is an innovative prognostic tool to support hepatologists, hepatobiliary surgeons and multidisciplinary teams in deciding on the best therapeutical approach for a patient with Hepatocellular Carcinoma, the most…
- Conditions
- Hepato Cellular Carcinoma (HCC), Liver Resection, Liver Transplantation
- Trial name
- NCT06894524
- Volunteers
- 200 people
- Sponsor
- Ophiomics
Hepato Cellular Carcinoma (HCC)
HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
This study will evaluate the efficacy and safety of therapy perioperative treatment with HAIC combined with donafenib and sintilimab (group A)/ donafenib combined with sintilimab (group B) compared with direct surgery (group C)…
- Trial name
- NCT06812039
- Testing
- HAIC combined with sintilimab and donafenib, Sintilimab and Donafenib, Surgery
- Where
- 3 sites in China
- Volunteers
- 165 people
- Sponsor
- Fudan University
Hepato Cellular Carcinoma (HCC)
PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
This is a single-arm, phase II clinical trial evaluating the safety and efficacy of PD-L1 antibody combined with bevacizumab and hepatic arterial infusion chemotherapy (HAIC) for patients with advanced unresectable hepatocellular…
- Trial name
- NCT06742424
- Testing
- PD-L1 antibody, Bevacizumab, HAIC-FOLFOX
- Where
- China
- Volunteers
- 36 people
- Sponsor
- West China Hospital